Common questions
Ipamorelin: direct answers, cited
The questions people actually ask, answered from the published record. No dosing.
Does ipamorelin reduce belly fat?
No human study has measured ipamorelin on belly fat. The closest data is a 2024 ferret study where intraperitoneal ipamorelin (1–3 mg/kg) inhibited chemotherapy-induced body-weight loss by about 24% via a peripheral mechanism — the opposite of a fat-loss result [5]. In mice, ipamorelin actually raised fat-pad weights [7]. Any belly-fat claim is extrapolation, not a measured ipamorelin finding.
What are the downsides of ipamorelin?
The headline downside is that it failed its one human efficacy test: the Phase 2 ileus trial (NCT00672074, n = 114, 0.03 mg/kg IV twice daily for up to 7 days) missed its primary endpoint, 25.3 h versus 32.6 h on placebo (p = 0.15) [3]. Beyond that: no long-term human safety data, a class-level cardiac signal from a related agonist [6], and unverified research-grade supply quality.
Does ipamorelin make you hungry?
It can, in animals. Ipamorelin acts on the ghrelin (hunger) receptor, and central administration of ghrelin-type secretagogues activates appetite centers and induces feeding in rats [8]. Two weeks of subcutaneous ipamorelin raised body weight ~15% with elevated leptin in mice [7]. In community reports, increased appetite after injection is occasionally described, generally milder than with GHRP-6 (anecdotal).
Does ipamorelin increase appetite?
Mechanistically yes — it is a ghrelin-receptor agonist, and ghrelin is the body's appetite-stimulating hormone, so central activation of these receptors induces feeding in rats [8]. Ipamorelin also stimulated adiposity and leptin in both growth-hormone-deficient and intact mice, indicating a growth-hormone-independent appetite/fat effect [7]. Community accounts describe this as real but usually milder than older GHRPs (anecdotal, not clinical evidence).
Does ipamorelin cause water retention?
No controlled human study has quantified water retention with ipamorelin. Growth-hormone excess is associated with sodium and water retention generally, and in the only human trial — a short 7-day IV course — no ipamorelin-specific safety signal was reported, though that window was brief [3]. In community reports, mild transient puffiness in the first few weeks is occasionally described and said to resolve (anecdotal).
What is ipamorelin?
Ipamorelin is a synthetic pentapeptide (Aib-His-D-2-Nal-D-Phe-Lys-NH2) that selectively activates the ghrelin / GHS-R1a receptor to release a pulse of growth hormone. In its founding characterization it released GH potently in rat pituitary cells, rats, and swine (swine ED50 2.3 nmol/kg) yet did not raise ACTH or cortisol even above 200× its GH ED50 — the first highly GH-selective secretagogue [1].
What does ipamorelin do for you?
In studies, ipamorelin triggers a selective pulse of growth hormone without raising cortisol or prolactin [1]. In animals that translates into longitudinal bone growth [4] and, separately, increased adiposity and appetite [7]. The one human efficacy trial (postoperative ileus) did not beat placebo [3]. It is not approved for any use, so it does nothing prescribable — this site documents what the research measured, not a personal benefit.
What is ipamorelin peptide?
"Ipamorelin peptide" is the same molecule — a five-amino-acid synthetic peptide, sequence Aib-His-D-2-Nal-D-Phe-Lys-NH2, derived from GHRP-1 [1]. The non-natural Aib residue and D-amino acids resist enzymatic breakdown. It is a selective agonist of the ghrelin receptor (GHS-R1a), defined by raising growth hormone without the cortisol and prolactin rise seen with less selective GHRPs [1].
What are the risks of ipamorelin?
The documented risks are evidentiary and mechanistic rather than observed: no long-term human safety data, one failed Phase 2 trial [3], a class-level cardiotoxicity signal from a related GHS-R1a agonist in rats [6], theoretical IGF-1/cancer and glucose concerns from growth-hormone-axis activation [1][15], and unverified purity of gray-market material. No ipamorelin trial has reported serious compound-specific harm, but the safety database is thin.
Why is ipamorelin being discontinued?
Ipamorelin was never an approved product, so there is nothing to discontinue in the usual sense. Its clinical development stopped because the only indication that reached Phase 2 — postoperative ileus — failed: the trial missed its primary endpoint (25.3 h vs 32.6 h, p = 0.15) and no further development followed [3]. Separately, in 2024 the FDA tightened compounding-pharmacy access by removing ipamorelin acetate from the interim 503A Category 2 list.
What does CJC-1295 and ipamorelin do?
They target two different receptors to raise growth hormone — CJC-1295 the GHRH receptor, ipamorelin the ghrelin (GHS-R1a) receptor — so together they are meant to produce a larger pulse [1]. The only combination-specific evidence is a 2026 narrative review noting improved muscle tetanic tension in a murine glucocorticoid muscle-loss model, with the caveat that evidence is limited to animal studies [16]. No human outcome trial of the pair exists.
Does ipamorelin increase IGF-1?
Not reliably in short studies. In the 15-day rat bone-growth study, ipamorelin raised bone-growth rate with no measurable change in total IGF-1 [4]. In diabetic mice, IGF-1 was actually suppressed despite growth-hormone hypersecretion, due to hepatic growth-hormone resistance [10]. IGF-1 can rise with sustained growth-hormone elevation — for example, ipamorelin plus a glucocorticoid raised IGF-1 in rats [12] — but it is context-dependent, not automatic [4].
How does CJC-1295 ipamorelin work?
Ipamorelin activates the ghrelin receptor (GHS-R1a) on pituitary growth-hormone cells, releasing a discrete GH pulse without raising cortisol or prolactin [1]. CJC-1295 is a GHRH analog acting on the separate GHRH receptor. Because the two pathways are distinct and complementary, the pairing is designed to amplify the GH pulse beyond what either produces alone — though this is mechanism, not a combination proven in human trials [1].
How much CJC-1295 ipamorelin should I take?
No peer-reviewed human dose exists for the combination, so this site gives none. The pair has never been tested in a controlled human trial, and the only combination result in the literature is a murine muscle study [16]. Community protocols are anecdotal conventions without controlled-trial support. The solid pharmacokinetic facts are single-agent: ipamorelin's ~2-hour half-life and ~40-minute GH pulse [2] — mechanism, not a dose.
Does CJC-1295 ipamorelin work?
Each component does what it is designed to do pharmacologically, and one murine study showed the pair improved muscle tetanic tension under glucocorticoid stress [16]. But no controlled human trial has tested the combination for body composition, recovery, or any outcome people pursue [16]. The honest answer: mechanistically plausible, animal-suggestive, human-unproven.
How to reconstitute CJC-1295 ipamorelin 5mg?
Ipamorelin is supplied as a lyophilized powder (free base or acetate salt) and reconstituted with bacteriostatic water for research handling; as a peptide it degrades with heat and freeze-thaw, so solution is typically refrigerated. These are general handling notes from the research-supply literature, not a clinical preparation instruction. Human pharmacokinetics were characterized only for IV dosing (~2-hour half-life) [2], not for self-prepared subcutaneous use.
How long does ipamorelin stay in your system?
In healthy human volunteers, ipamorelin has a terminal half-life of approximately 2 hours, with clearance 0.078 L/h/kg and steady-state volume of distribution 0.22 L/kg; the growth-hormone pulse peaks about 40 minutes after dosing [2]. As a roughly 2-hour half-life, the parent peptide is largely cleared within a day. In rats, plasma clearance is about 5-fold lower than GHRP-6 [11].
Will I gain weight on ipamorelin?
In animals, weight gain is plausible: two weeks of subcutaneous ipamorelin raised body weight ~15% with higher fat-pad weights and leptin in mice [7], and a ghrelin-receptor mechanism stimulates appetite [8]. In humans there is no body-composition trial; the only human efficacy trial was for bowel recovery, not weight [3]. Whether weight changes depends on the same diet and training as anything else — the studies measured animals, not you.
What does ipamorelin peptide do?
It selectively releases a pulse of growth hormone by activating the ghrelin receptor (GHS-R1a), without raising cortisol or prolactin even at high doses [1]. In animals that produces longitudinal bone growth [4] and, through a separate route, increased appetite and adiposity [7][8]. Its one human efficacy trial did not beat placebo [3], and it is not approved for any use.
How long does it take for ipamorelin to work?
Pharmacologically, fast: the growth-hormone pulse peaks about 40 minutes after a dose in human pharmacokinetic work [2]. For reported effects, community accounts describe sleep changes within one to two weeks and any leaner-appearance shift only from about week five onward (anecdotal, not clinical evidence) [as reported on /effects]. No controlled human study has timed a body-composition effect.
Where to inject CJC-1295 ipamorelin?
This site does not give injection instructions. In research, subcutaneous administration is the dominant route for rodent body-composition studies and for off-label community use, while the human pharmacokinetic and clinical data used the intravenous route [2][3]. The combination CJC-1295 plus ipamorelin has no controlled human trial defining any administration protocol [16], so any specific injection-site guidance circulating online is anecdotal, not evidence-based.
Does ipamorelin cause cancer?
No ipamorelin study has shown it causes cancer, and no human carcinogenicity trial exists. The concern is theoretical and mechanistic: growth hormone drives IGF-1, a known mitogen, so chronically raising growth-hormone pulses raises a hypothetical concern about pre-existing tumors [1]. The only human trial (7-day IV course) reported no compound-specific safety signal but was far too short to assess cancer risk [3]. This remains an open, unresolved question, not a demonstrated effect.